Fourteen 8-hydroxyquinolines were tested for antiplaque activity by measuring their minimum inhibitory concentrations [MIC (M)] against Streptococcus mutans No. 6715. Linear regression analysis was conducted with the MIC (M) values and hydrophobic (log P), electronic (beta, pKaOH, pKaN), and steric [molar refractivity (MR), molecular weight (mol wt)] parameters. The best correlation (r2 = 0.90) was obtained with MR, log P, and beta. The smaller the steric contribution of the 5-substituent, the more active the compound. The parent 8-hydroxyquinoline was the most active. The negative contribution toward activity by 5-substituents larger than hydrogen can be overcome by the positive contributions of groups that are lipophilic and electron withdrawing; for example, the 5-chloro derivative is as active as the parent 8-hydroxyquinolines.

No abstract

Background: Present methods for measuring serum total iron-binding capacity (TIBC) involve manipulation of samples or performance of two assays on each sample. We developed a direct automated assay (DTIBC) for TIBC. Methods: We added to serum a saturating amount of iron bound to an excess of chelating dye at a low pH, recorded a blank reading that represented the sum of the saturating amount of iron plus the serum iron, and then added a strong neutral pH buffer. The decrease in absorbance (as transferrin extracts iron from the iron-dye complex) is directly proportional to the TIBC. TIBC values for 125 patients were determined by DTIBC, alumina column TIBC (AC), magnetic particle TIBC (MTIBC), and the UIBC method (UIBC) on Roche COBAS FARA and Mira chemistry analyzers. In a separate study, TIBC values for 128 patients were determined on an Olympus AU400 by the DTIBC and the MTIBC methods. Results: Methods comparisons on the COBAS analyzers yielded the following results: DTIBC = 1.05(MTIBC) − 1.0 μmol/L (r = 0.987; Sy|x = 2.6 μmol/L); DTIBC = 1.07(AC) − 1.0 μmol/L (r = 0.982; Sy|x = 3.0 μmol/L); and DTIBC = 1.14(UIBC) + 3.4 μmol/L (r = 0.982; Sy|x = 3.0 μmol/L). A similar correlation study using the Olympus AU400 yielded DTIBC = 1.00(MTIBC) − 0.1 μmol/L (r = 0.983; Sy|x = 2.7 μmol/L). The assay was linear from 12.5 to 125 μmol/L (70–700 μg/dL) TIBC on the COBAS FARA. Within- and between-run imprecision (CV) was ≤4.8% at two concentrations. Plasma samples were unsuitable for the method. No interference was seen with common interferants other than ascorbate, deferoxamine, and ferrous sulfate, and only at concentrations well above normal. Conclusion: The new DTIBC assay is suitable for routine use in clinical laboratories and may improve the quality of iron metabolism studies.

No abstract

No abstract